Interferons (IFNs) have been proposed as a treatment for multiple sclerosis (MS) because of the evidence that a viral infection, an immunoregulatory defect' or both may be implicated in the pathogenesis of the disease. Defective production of type I IFN and reduced natural killer (NK) activity in peripheral blood have been reported in MS patients' and it is known that natural beta IFN is a booster of NK activity. 5 Intrathecally administered beta-IFN has been reported to reduce exacerbation rate in relapsing-remitting MS patients,6 while no effect was observed when beta-IFN was given intravenously. 7 Patients and methods Clinically definite MS," both relapsingremitting (RR) and progressive (P) patients were included, according to the course of the disease in the year preceding the entry. Selection criteria included: active disease (one or more exacerbations per year for RR patients or an increase of one or more points of disability score (DS) in the last two years for P patients), no corticosteroids or immunosuppressive treatment in the previous three and six months respectively, DS at entry less than seven.'2 Before entry, all patients were regularly followed in our outpatient clinic, most since the onset of the disease or for at least two years. Informed consent was obtained from all patients. The study was approved by the Regional Scientific Committee.
One million units of beta IFN were injected by lumbar puncture twice in the first week, then weekly for the next three weeks and monthly for five months.
At each lumbar puncture CSF was obtained for analysis. Control patients had a sham lumbar puncture (that is, subcutaneous injection of 2 ml of distilled water) according to the same schedule; a true lumbar puncture was performed at the beginning and the end of treatment for CSF analysis. To preserve the blind nature of the trial, both recipient and control patients took indomethacin im 50 mg every six hours on the day of each treatment to reduce the side effects of IFN.
Natural beta IFN (Cytotech-Martigny CH) was produced by stimulation of human foreskin fibroblasts (FS 4) by Poly-I, Poly-C and subsequent purification by silicic acid and zinc-chelate chromatography. MRI Neurological examination with scoring for disability"2 was performed by a physician blind to the trial on the day preceding each lumbar puncture and every three months after the treatment cycle. An additional neurological assessment was performed for new episodes. An episode is defined as the occurrence of new symptoms and signs, lasting for more than 24 hours. Progression rate was calculated by dividing DS or changes in DS by the relevant period of time in months (overall pre-trial disease duration, or two years preceding the trial, or six months treatment period, or two years follow up).
A) Clinical results
Sixteen patients were included in the study. Eight (three males and five females) were randomly assigned to IFN, and eight (two males and six females) to the control group. Their clinical data before entry are shown in table 1 . Except for the progression rate, which is slightly higher in the control group, no significant differences existed between the two treatment groups.
In February 1989, patients had been followed for 10-24 months: mean follow up was 22-7 months for treated patients and 21 months for controls. Compared with the two year pretrial value, mean relapse frequency (number of episodes/patient/year) during treatment was significantly increased in recipients (from 1 -87 to 5, p = 0 01), while it was unchanged in controls. During the six months of treatment, the annual relapse frequency was higher in IFN-treated than in placebo-treated patients (5 versus 1-5, p = 0 005) (fig 1) . At the end of the follow up, episode frequency was still higher in recipients than in controls (2-88 versus 1 77/ year) but this difference did not reach statistical significance (p = 0117) (fig 1) . During the entire follow up, all patients, both RR and P, displayed episodes (frequency range from 0-6-5-5 (treated), 0-5-5-2 (control)) during the treatment; episodes occurred in all treated patients (from two to 10 per year), and in four of the eight controls (from two to four per year). Two RR patients (one IFN and one placebo) started to progress during the study. At the end of the follow up, deterioration of neurological conditions occurred both in treated (mean DS 5-7) and in controls (mean DS 5-4) (p = 0 48). During the period of treatment, increase in DS was more marked in treated patients (from 4-12 to 5-2) than in controls (from 4 62 to 4-7), but difference was not statistically significant (p = 0-68) (fig 2a) . However, more patients in the treated (7/8) Progression rate increased in recipients during treatment (from 0-06 to 0 17), and returned to the pre-study value at the end of follow up (0 07). Compared to the pre-study value the differences were not significant (p = 0-24 at six months and p = 0-32 at the end of follow up). However, PR was significantly higher in recipients (017) than in controls (0) during treatment, even if care was taken not to assess DS during the episodes (fig 3) . The difference was significant (p = 0-005), due both to deterioration in treated patients and to improvement in controls. Before treatment, MRI was positive for multiple areas of demyelination in all patients. At the end of the treatment, MRI findings were worse in three and unchanged in five of the recipients, while in the control group they had deteriorated in two, unchanged in five and improved in one. Variation of MRI aspects did not correlate with the clinical evolution both in treated and in control patients.
Side effects were more frequent and more noticeable in treated than in control patients (table 2) . In treated patients, fever (less than 38 5°C) subsided within the 48 hours after injection; in some patients two peaks (at six and 30 hours) and in others a single peak (at eight or 24 hours) were observed. Episodes occurring during the six month treatment period were not related to hyperpyrexia. Myalgia, asthenia and nausea were also more frequently reported by treated patients than by controls, and were experienced on more than one occasion. Headache was also an equally frequent complaint in treated and control patients. Despite the higher frequency of side effects in recipients, blindness of the study was not hampered: nine patients thought that they had (fig 4) . In individual patients no clear correlation was found between T-cell subset fluctuations and clinical exacerbations. Beta-IFN concentrations were analysed in CSF and serum in two treated and three control patients: concentrations in CSF reached a peak at the second lumbar puncture in treated patients, but fell quickly to be undetectable at the sixth and eighth lumbar puncture. IFN was N 
